(Q40334868)

English

Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment

scientific article published on 4 January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment (English)

1 reference

Europe PubMed Central

19 September 2017

ovarian carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Villedieu M

1

1 reference

Europe PubMed Central

19 September 2017

Deslandes E

2

1 reference

Europe PubMed Central

19 September 2017

Duval M

3

1 reference

Europe PubMed Central

19 September 2017

Héron JF

4

1 reference

Europe PubMed Central

19 September 2017

Gauduchon P

5

1 reference

Europe PubMed Central

19 September 2017

Poulain L

6

1 reference

Europe PubMed Central

19 September 2017

language of work or name

0 references

publication date

4 January 2006

1 reference

Europe PubMed Central

19 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

19 September 2017

101

1 reference

Europe PubMed Central

19 September 2017

3

1 reference

Europe PubMed Central

19 September 2017

507-519

1 reference

Europe PubMed Central

19 September 2017

Cancer of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Overexpression of metallothionein confers resistance to anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Cellular processing of platinum anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Ovarian cancer: strategies for overcoming resistance to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Options for modulation of drug resistance in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Resistance to cytotoxic agents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

AKT/PKB signaling mechanisms in cancer and chemoresistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Cisplatin: mode of cytotoxic action and molecular basis of resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

MAP kinases and cell migration

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Features of apoptotic cells measured by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Multiple drug resistance in the human ovarian carcinoma cell line OAW42-A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Collateral resistance to photon and neutron irradiation is associated with acquired cis-platinum resistance in human ovarian tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Hypermethylation of the PTEN gene in ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Requirement for ERK activation in cisplatin-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.017

7 January 2021

Identifiers

10.1016/J.YGYNO.2005.11.017

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40334868&oldid=1895551011"